A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients With Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2018
At a glance
- Drugs Evinacumab (Primary) ; Evinacumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 02 Oct 2018 The trial in Japan has not yet started with the recruitment.
- 31 Aug 2018 Biomarkers information updated
- 19 Jun 2018 Planned End Date changed from 5 May 2020 to 30 Mar 2020.